Skip to main content
Retour
Watch Compare

Citius Pharmaceuticals, Inc.

Qualité des données : 83%
CTXR
Nasdaq Manufacturing Chemicals
0,81 €
▼ 0,04 € (-4,51%)
Cap. Boursière: 18,85 M
Prix
0,84 €
Cap. Boursière
18,85 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -34,84 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-53,58%
En dessous de la moyenne du secteur (-53,41%)
ROIC-33,29%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,99
Interest Coverage-182,70

Valorisation

PE (TTM)
-0,49
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,24
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,5 -1,5
P/B 0,2 1,6
ROE % -53,6 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -38,85 M
ROE -53,58% ROA -28,99%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -34,84 M
ROIC -33,29% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,99
Interest Coverage -182,70 Asset Turnover N/A
Working Capital -261 987 Tangible Book Value 70,61 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,49 Forward P/E N/A
P/B Ratio 0,24 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -184,83%
Market Cap 18,85 M Enterprise Value 11,13 M
Per Share
EPS (Diluted TTM) -2,46 Revenue / Share N/A
FCF / Share -1,56 OCF / Share -1,56
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 89,66%
SBC-Adj. FCF -47,06 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -39,74 M -39,43 M -32,54 M -33,64 M -23,05 M
EPS (Diluted) -3,38 -5,97 — -0,23 —
Gross Profit — — — — —
Operating Income -38,53 M -42,00 M -36,73 M -33,32 M -23,53 M
EBITDA — — — — —
R&D Expenses 9,16 M 11,91 M 14,82 M 17,66 M 12,24 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 49 750,0 — — 10 839,0 10 839,0
Income Tax 1,06 M 576 000,0 576 000,0 576 000,0 1 233,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 130,94 M 116,65 M 103,61 M 114,00 M 142,43 M
Total Liabilities 53,41 M 42,55 M 12,18 M 10,57 M 9,65 M
Shareholders' Equity 67,55 M 70,08 M 90,83 M 102,83 M 132,18 M
Total Debt — — — — —
Cash & Equivalents 4,25 M 3,25 M 26,48 M 41,71 M 70,07 M
Current Assets 27,93 M 14,22 M 34,37 M 44,56 M 72,81 M
Current Liabilities 44,91 M 35,81 M 5,78 M 4,53 M 3,98 M